Background
Adults over the age of 60 with symptoms of major depressive disorder are said to have late-life depression (LLD), a condition that usually decreases a person's quality of life and is associated with other risks like physical frailty and dementia. A common feature of more severe LLD is psychomotor slowing, where a person's ability to think and move are impaired. For example, they might not be able to walk or process information as quickly, and they might have problems with their working memory.
Psychomotor slowing in LLD might be the result of a problem with the way a person's body produces or responds to the neurotransmitter dopamine. The drug Levodopa (L-DOPA), which can replace missing dopamine in the brain, has been used to treat to treat Parkinson's disease for many decades, and it might also affect psychomotor slowing in LLD.
Methods
In this study, participants are adults aged 60 years or older with moderate to severe major depression. Participants undergo the "L-DOPA challenge"-a 2-week period where they receive a dose of L-DOPA once a day for the first week and a dose of L-DOPA twice a day for the second week. Before and after a participant completes the L-DOPA challenge, the study team assesses their depressive symptoms and psychomotor function. After the L-DOPA challenge, if a participant still shows signs of moderate or severe depression, they receive an antidepressant for 12 weeks.
Aims
The first aim of this study is to test the feasibility of the L-DOPA challenge-that is, whether most of the 50 participants recruited for this study will complete the L-DOPA challenge. For example, participants might have to withdraw if they can't make the daily visits to the research site to receive their L-DOPA medication, if they can't tolerate the medication's side effects, or if their depressive symptoms get significantly worse. Our hypothesis is that 80% of the participants will complete the L-DOPA challenge.
The second aim of the study is to see if L-DOPA affects participants' depressive symptoms, processing speed, and working memory. Our hypothesis is that L-DOPA response, measured as an improvement in gait speed, is associated with a decrease in depressive symptoms and an increase in processing speed and working memory.

开始日期2024-08-15

申办/合作机构

University of British Columbia

[+1]

NCT06365515

/ RecruitingN/AIIT

Dopamine and Reward Learning Across Hormonal Transition Phases

Hormonal transition periods during the menstrual cycle may predispose women to mental disorders. Hormonal fluctuations provide specific neuroendocrine conditions that modulate brain structure and function and these actions affect cognitive and emotional behaviors and affect energy and mood homeostasis. It is thought that these changes are driven by altered dopamine transmission. Here, the investigators aim to examine (1) how sex hormones and dopamine are linked and also (2) how hormonal changes affect motivation, mood, and energy homeostasis.
To this end, dopamine intervention will be tested on effort-based decision-making and motivational circuits in three hormonal stages (i.e., women in early-follicular phase (EF), women in mid-luteal phase (ML), and men). Additionally, the effects of hormonal status on metabolic indices will be tested, and its effects on mood fluctuations in a period of a month.
The investigator hypothesizes that women in EF cycle phase (1) have naturally less dopamine and show less effort, and (2) they show greater improvement in effort-based decision-making after Levodopa administration. The investigator has exploratory outcomes about (3) sex differences in reward-learning with and without Levodopa administration and explores if these differences correlate with elevated female sex hormone levels. Moreover, it is hypothesized that (4) hormonal fluctuations affect energy homeostasis, thus women in their EF cycle phase have higher energy expenditure and (5) they report more negative mood than in their mid-luteal (ML) cycle phase.

开始日期2024-05-01

申办/合作机构

Deutsche Forschungsgemeinschaft

[+1]

100 项与左旋多巴相关的临床结果

登录后查看更多信息

100 项与左旋多巴相关的转化医学

登录后查看更多信息

100 项与左旋多巴相关的专利（医药）

登录后查看更多信息

33,685

项与左旋多巴相关的文献（医药）

2026-01-01·TALANTA

Glutathione-based supramolecular chiral nanozyme for colorimetric enantioselective sensing of 3,4-dihydroxyphenylalanine

Article

作者: Han, Jie ; Huan, Xintong ; Li, Jiaying ; Jiang, Mingxin ; Zhang, Chenglong ; Sun, Xiaohuan

The determination of the absolute configuration and enantiomeric composition of chiral species is of great significance. Nevertheless, the accurate quantification through output signals related to the identity of chiral analytes has been rarely reported in this regard. In this study, through the self-assembly of glutathione (GSH) and Cu²⁺, supramolecular chiral nanoparticles (GSH-Cu²⁺) were constructed for the enantioselective sensing of chiral 3,4-dihydroxyphenylalanine (DOPA). It is found that GSH-Cu²⁺ exhibits excellent peroxidase-like activity, with a K_cat value of 2.20 × 10^-3 M s^-1 g^-1 toward 3,3',5,5'-tetramethylbenzidine (TMB). When chiral DOPA is employed as substrate, enantioselective catalysis is observed, with GSH-Cu²⁺ showing more favorable activity towards D-DOPA as compared to L-DOPA. Further mechanistic study demonstrates that the underlying principle lies in the more favorable adsorption of GSH-Cu²⁺ toward L-DOPA, which then forms a shielding layer that inhibits the catalytic activity. By exploiting the differential catalytic rates indicated by the ultraviolet-visible (UV-Vis) absorption change of dopachrome (the catalyzed product of DOPA), calibration curves, derived from signals related to their identities, that enable the determination of the absolute configuration and enantiomeric composition of D/L-DOPA, have been established and applied in real pharmaceutical detection. What is also important, the GSH-Cu²⁺-based sensing platform is demonstrated with high sensitivity (detection limit of 1.31 μM/1.51 μM for D/L-DOPA) and selectivity. Overall, this work enhances our understanding of enantioselective sensing using identity-involved output signals and provides new opportunities for enantioselective sensing with improved reliability.

2026-01-01·BIOMATERIALS

Minimally invasive upconversion optogenetics for Parkinson's disease treatment

Article

作者: Wang, Xiaoran ; Yu, Jiaojiao ; Li, Xinsheng ; Sun, Shao-Kai ; Xiang, Heng ; Liu, Ruxia ; Zhang, Cai ; Zhou, Ting

The treatment of Parkinson's disease (PD) is greatly limited by the side effects of levodopa, the current gold standard medication, which can cause severe motor complications. Optogenetic stimulation holds promise for PD therapy, but it has been plagued by invasive fiber insertion. Herein, we propose the minimally invasive treatment of PD using upconversion optogenetics for the first time. Channelrhodopsin-2 (ChR2) is expressed in the globus pallidus externus (GPe) brain region of PD mice, followed by in situ injection of upconversion nanoparticles (UCNPs). When near-infrared (NIR) light is delivered through a fiber fixed on the skull, UCNPs can convert NIR light into blue light, thereby effectively activating the GPe. Open field and rotarod tests demonstrate significant improvement in motor abilities and coordination in PD mice. Compared to conventional optogenetics, upconversion optogenetics not only achieves equivalent therapeutic effects but also avoids damage and inflammation caused by fiber insertion. Furthermore, this method can be extended to modulate neural activity in deep brain regions, including substantia nigra pars compacta and paraventricular nucleus of the thalamus, with neural activation effects lasting for up to one week. Our study presents a minimally invasive optogenetic strategy for PD treatment, with potential therapeutic applications in various neurological disorders.

2025-11-01·TALANTA

Unlocking the power of chirality: Surface nanoarchitectonics of modified halloysite nanotubes for enantioselective recognition

Article

作者: Arnaboldi, Serena ; Warakulwit, Chompunuch ; Matthayom, Punjapol ; Maggioni, Daniela ; Grecchi, Sara ; Niamlaem, Malinee

Developing cost-effective electrode materials with high performance for enantioselective recognition is rapidly gaining attention. In this work, we harness the unique physicochemical properties of halloysite nanotubes (HNTs) as innovative electrode platforms for chiral discrimination. We functionalized HNTs with an enantiopure oligomer based on thiophene units via chemical oligomerization using FeCl₃ as an oxidizing agent. The successful functionalization of the HNTs with the oligomer was further confirmed by both solid state ¹³C NMR and zeta potential studies (from -20.0 ± 1.5 mV to -12.4 ± 3.0 mV after modification). The resulting composite materials (oligo-(S)- and oligo-(R)- modified HNTs) demonstrated remarkable enantioselective recognition capabilities in terms of peak potential values (560-650 mV) when testing the enantiomers of DOPA, a chiral drug of pharmaceutical interest. These findings highlight the potential of HNT-based modified electrodes as a novel class of chiral electrochemical sensors, paving the way for advanced applications in enantioselective analysis.

727

项与左旋多巴相关的新闻（医药）

2025-08-23

·药时空

用大肠杆菌合成“升级版胶原蛋白”，组织工程迎来新材料革命

在再生医学领域，胶原蛋白一直是构建人体组织的黄金标准，但其动物来源带来的免疫风险和复杂生产工艺长期困扰着研究者。 Lital Alfonta 团队通过基因密码扩展技术，在大肠杆菌中表达胶原蛋白模拟肽（CMPs），并在特定位点掺入非经典氨基酸 L-DOPA。这种 CMP 以 GPP 重复序列模拟胶原蛋白的三螺旋结构，并通过半胱氨酸将 N 端的纤维化位点氧化形成二硫键，促进自组装，显著增强了 CMP 的结构稳定性。该系统利用合成生物学工具实现精准修饰，为组织工程提供了可定制、高生物相容性的胶原蛋白替代材料，有望推动再生医学和伤口修复领域的创新应用。 CMP的结构稳定性与自组装能力传统胶原蛋白依赖复杂的翻译后修饰维持结构，而团队设计的胶原模拟肽（(GPP)₁₂）通过N端半胱氨酸自发氧化形成三螺旋结构，完美模拟天然胶原特征。更突破性的是，他们利用遗传密码扩展技术，在肽链特定位点精准嵌入非天然氨基酸L-DOPA。这种源自海洋贻贝足蛋白的成分，拥有独特的双酚羟基结构，这些结果印证了 L-DOPA 通过促进分子间相互作用，增强 CMP 的结构稳定性和自组装能力，为其在组织工程中支持细胞黏附和生长提供了关键特性。冷冻透射电镜（Cryo-TEM）图像和纤维尺寸分析分子模拟显示，L-DOPA能形成分子间氢键和双醌交联，使纤维更粗更长。电镜观测证实，含L-DOPA的肽在氧化条件下形成长达7μm的纤维（比普通CMP长3倍），宽度也显著增加。这些结果印证了 L-DOPA 通过分子间氢键和双醌交联增强纤维形成能力，且纤维在生理条件下即可组装，克服了天然胶原蛋白需酸性条件的局限，为构建更有效的组织工程支架提供了依据。共聚焦成像和细胞实验分析当人源成纤维细胞接种在含L-DOPA-CMP的水凝胶薄膜上，10分钟内细胞粘附率暴增24倍！4天后细胞铺展面积增加50%，并呈现典型的纺锤形态，代谢活性提升300%。更惊人的是，L-DOPA肽自组装形成的薄膜无需其他支架，直接支持细胞生长。这些结果凸显了 L-DOPA 修饰的 CMP 片材在组织工程中促进细胞黏附与增殖的潜力，尤其适用于需快速细胞锚定的再生医学场景。共聚焦成像和代谢活性分析团队进一步将CMP与海藻酸盐耦合构建3D支架。L-DOPA的金属螯合特性使支架孔径更精细可控（钙离子浓度0.14%时孔径最优）。在3D培养中，含L-DOPA的支架内细胞均匀分布并自组织成层状结构，而对照组细胞则聚集成团。这些结果证实，L-DOPA 修饰的 CMP 与海藻酸盐构建的 3D 支架，可模拟天然细胞外基质，支持细胞黏附、铺展及组织化生长，为组织工程中 3D 培养体系的设计提供了关键依据，尤其适用于需要构建复杂组织结构的再生医学领域。该技术突破不仅解决了动物胶原的安全隐患，更通过“分子乐高”策略实现材料性能精准调控：通过调整肽浓度和交联剂用量，可自由控制纤维长度（0.5-7μm）和支架孔径（50-200μm）。这种可基因编码的胶原平台为软骨再生、创伤修复等应用提供了无限可能。参考文献：Pasi Deutschman M, Zevi G, Chen S, et al. Enhanced Cell Adhesion Properties of a Collagen‐Mimicking Peptide Through Site‐Specific L‐DOPA Incorporation[J]. Advanced Functional Materials, 2025, 35(11): 2414899. DOI:10.1002/adfm.202414899 识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

免疫疗法临床结果

2025-08-20

·卫医荟

帕金森 | 帕金森病患者的冻结步态临床预测因素：一项系统综述

本周解读： Clinical predictors of freezing of gait in patients with Parkinson's disease: A systematic review 帕金森病患者的冻结步态临床预测因素：一项系统综述 Alshimemeri S, Alhayssoni A, Hazazi R. Clin Neurol Neurosurg. Published online March 12, 2025. 背景：冻结步态（FOG）是帕金森病（PD）最严重的致残性症状之一，超过50%的PD患者合并FOG，其严重影响患者的日常生活质量和活动能力。对FOG的早期征象进行预测将有助于尽早拟定针对性预防策略。目的：本系统综述旨在确定PD-FOG的相关的临床预测指标，以便于FOG的早期预测并及时干预。方法：在PubMed、EBSCO和Web of Science三大数据库中进行系统文献检索。纳入标准为2003年1月至2023年6月发表的有关PD患者的FOG预测因素的随机对照试验、队列研究和系列病例分析。结果： 9项研究符合纳入标准。较高的基线统一帕金森病量表（MDS-UPDRS）评分（反映疾病严重程度更高）、较高的左旋多巴（LD）剂量和较早启用LD，是PD患者发生FOG的预测因素。此外，较高的姿势不稳与步态障碍（PIGD）评分、运动波动和下肢受累会增加FOG的发生风险。其他与FOG风险增加相关的因素包括高龄、疾病病程长、焦虑、嗅觉减退、认知障碍和睡眠障碍。此外，采用视觉评估发现步幅缩短也可作为FOG的预测因素。早期使用司来吉兰、金刚烷胺及多巴胺受体激动剂可有助于降低FOG的发生率（见图）。图抗帕金森病药治疗3年后FOG发生率比较（原始数据来源于系统综述纳入文献：Zhang H, et al. Medicine (Baltimore). 2016 Jun;95(26):e4056.）结论：疾病严重程度、LD的早期服用的较高剂量、症状波动、PIGD症状严重、会增加FOG的发生风险。焦虑、认知障碍和嗅觉减退等非运动因素也可能与FOG相关。针对PD患者的临床特征制定个体化的治疗方案，将有助于减少FOG的发生。专家点评：帕金森病患者常见步态与姿势异常问题，尤其冻结步态、慌张步态等，非常容易导致跌倒和受伤。冻结步态成因复杂，与疾病进展和药物治疗均有关，需要谨慎和尽早干预。这篇系统综述提出，尽早添加司来吉兰或金刚烷胺有助于降低冻结步态的发生。与《2025中国PD步态障碍管理专家共识》推荐是一致的，共识推荐MAO-B抑制剂（B级推荐）或金刚烷胺（C级推荐）用于改善冻结步态和其他步态障碍，但金刚烷胺的改善作用可能随着治疗时间的推移而减退[1]。专家简介雷立芳中南大学湘雅三医院神经内科副主任，神经病学博士/博士生导师。主要研究方向为：运动障碍疾病、神经变性病与遗传病的诊断治疗。目前任湖南省医学会神经病学分会帕金森病与运动障碍学组副组长，中国卒中协会遗传分会委员，中国微循环学会神经变性病专委会委员，是湖南省首届高层次医药卫生骨干人才，中南大学湘雅三医院“至善领跑计划”人才，美国UCDavis医学中心（2015年）及美国路易斯安娜州立大学（2019年）访问学者。2019年获国家自然科学基金面上项目资助1项，主持完成湖南省自然科学基金面上、湖南省科技计划项目及湖南省卫计委科研项目多项，发表相关论文30余篇，其中以一作或通讯作者发表SCI论文6篇参考文献共1篇 [1] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍学组. 中华神经科杂志，2025，58(03)228-243. 仅供医学人士参考

临床研究

2025-08-19

·PRNewswire

Innovation in the Fight Against Parkinson's: Stimvia's Non-Invasive URIS® Therapy Shows Success in Clinical Study

OSTRAVA, Czech Republic, Aug. 19, 2025 /PRNewswire/ -- Stimvia, a medtech company based in the Czech Republic, has successfully completed a clinical study on peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) through its URIS® device to treat Parkinson's disease symptoms. Results, published in Clinical Parkinsonism & Related Disorders, confirm the safety of this non-invasive treatment and suggest a positive impact on symptom relief, particularly tremor, and patients' quality of life. "Patients experienced visible improvements not only in motor symptoms like resting tremor, but more importantly in their everyday comfort and well-being. The changes in quality-of-life questionnaires exceeded the threshold of clinical relevance. And most importantly—there were no severe side effects," says Prof. MUDr. David Skoloudik, Ph.D., FESO, FEAN, principal investigator of the study and Vice Dean for Science and Research at the Faculty of Medicine, University of Ostrava. The study included 12 Parkinson's patients taking Levodopa, a medication that alleviates symptoms but tends to lose effectiveness over time, producing more side effects. The goal was to determine whether URIS® could serve as a meaningful complement to standard treatment. Over six weeks, participants used the URIS® device for daily 30-minute stimulation of the peroneal nerve behind the knee, followed by six weeks without stimulation to observe if the positive effects would persist. The greatest benefits were reported in daily functioning: patients experienced less discomfort, improved ability to perform activities, and an overall increase in quality of life—especially due to a significant reduction in tremor. These improvements surpassed the clinically significant threshold, meaning they had a real, measurable impact on patients. "With the combination of Levodopa and non-invasive neuromodulation, we aim to slow the progression of the disease and extend patients' quality years of life—without the need for invasive procedures such as deep brain stimulation. We're already seeing that URIS® may be a more suitable option in the early stages of Parkinson's, thanks to its non-invasive nature, ease of home use, and strong safety profile," says Lukas Doskocil, CEO of Stimvia. An indicator of the therapy's value, according to Stimvia, is that after the, 80% of the patients from the pilot study voluntarily chose to continue using URIS® therapy after the initial phase. Stimvia is now preparing a larger international clinical trial this fall to confirm these promising results. Logo - SOURCE Stimvia WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床研究

100 项与左旋多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00059	左旋多巴	N04BA01	DB01235

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
帕金森病	美国	Hoffmann-La Roche, Inc.	1970-06-04
帕金森病	美国	Shire Development LLC	1970-06-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
运动失调	临床3期	美国	AbbVie, Inc.	2009-06-01
运动失调	临床3期	德国	AbbVie, Inc.	2009-06-01
运动失调	临床3期	新西兰	AbbVie, Inc.	2009-06-01
哮喘	临床1期	美国	Acorda Therapeutics, Inc.	2015-12-01
吸烟	临床1期	美国	Acorda Therapeutics, Inc.	2015-12-01
自闭症谱系障碍	临床前	中国	复旦大学	2025-07-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


PD MED early disease randomisation (MDS2023)	N/A	帕金森病	1,593	Levodopa-sparing therapy (dopamine agonist or monoamine oxidase B inhibitor)	顧鏇鏇襯鬱窪憲選窪鏇(夢鹹廠夢簾繭齋獵遞網): P-Value = 0.84 更多	积极	2023-08-27
				Levodopa alone
NCT03761030 (CTgov)	临床4期	癫痫持续状态 \| 重度抑郁症	51	L-DOPA (L-DOPA Arm)	簾積衊齋壓鏇淵鏇衊積(願構淵積醖構繭齋窪觸) = 製蓋糧餘鹽繭製製醖淵選蓋鑰積構顧窪繭繭艱 (構襯艱遞齋繭鏇構鑰鏇, 6.4) 更多	-	2023-05-22
				Placebo Oral Tablet (Placebo Arm)	簾積衊齋壓鏇淵鏇衊積(願構淵積醖構繭齋窪觸) = 淵鹽顧築廠築憲獵夢壓選蓋鑰積構顧窪繭繭艱 (構襯艱遞齋繭鏇構鑰鏇, 5.8) 更多
SPAN-PD (AAN2023)	临床3期	帕金森病	-	CVT-301 84mg	願憲廠築鹽網遞獵餘夢(艱憲簾糧艱廠淵蓋顧築) = 蓋積窪夢襯觸齋簾鏇繭簾簾膚網餘壓鹹鬱簾窪 (鑰選繭繭鬱顧廠遞構顧 )	积极	2023-04-25
P13-11.014 (AAN2023)	N/A	帕金森病	33	Intrajejunal Levodopa Infusion (ILI)	壓憲製餘鏇鏇齋淵獵繭(獵積醖顧廠願蓋觸鏇窪) = Most common complications were PEG-J tube dislodgement and pump malfunction in 18 (54.5%) patients over the study period. 遞簾鬱衊鏇獵構鹽鏇繭 (醖鏇網齋憲壓積壓觸簾 ) 更多	-	2023-04-25
EAN2022	临床2期	帕金森病	24	Total daily LD/CD dose of 400/100 mg 4 intakes a day every 4 hours (Q4H) plus OPC 50 mg	艱廠構廠鹽膚襯壓夢壓(淵鏇構廠艱獵鑰蓋築製) = The Q3H plus OPC regimen was also associated with an increase in LD Cmin with no significant impact on LD Cmax, leading to a ~60–90% decrease in the LD fluctuation (variation between Cmax and Cmin) 艱艱顧鏇壓壓顧醖構蓋 (壓衊窪齋鬱齋糧齋襯鹽 ) 更多	积极	2022-06-24
				Total daily LD/CD dose of 400/100 mg 5 intakes a day every 3 hours (Q3H) plus OPC 50 mg
CVT-301 (MDS2021)	临床3期	帕金森病	709	CVT-301 84 mg	襯鏇鏇築獵繭壓遞鑰壓(網獵積遞積糧觸簾膚簾) = More patients achieved and maintained an ON state within 60 minutes postdose vs placebo 艱鑰淵製壓遞鹹鹹積製 (獵構齋製淵憲鹹糧選範 ) 更多	积极	2021-09-17
				Placebo
MDS2020	N/A	帕金森病一线	360	Levodopa	淵鬱廠遞選鬱淵顧淵憲(壓選築鹽壓憲壓憲淵窪) = 構繭鹹餘遞簾遞齋鹽鬱網餘願築餘壓鹹鬱獵網 (積醖膚構襯鹽廠鹹廠獵, 3 ~ 15.49)	积极	2020-09-12
NCT03541356 (THOR201, CTgov)	临床2期	帕金森病	32	Placebo (Placebo)	齋網繭繭襯構憲鏇製鑰 = 遞鬱選顧鹽鑰廠鹹鑰蓋繭獵憲齋壓繭壓餘夢遞 (選鑰壓醖網鏇製範衊觸, 襯齋廠築糧廠網窪獵襯 ~ 築襯遞鹽積選憲範願願) 更多	-	2020-08-12
				L-dopa 35 mg (L-dopa 35 mg)	齋網繭繭襯構憲鏇製鑰 = 範選製窪壓繭壓膚觸蓋繭獵憲齋壓繭壓餘夢遞 (選鑰壓醖網鏇製範衊觸, 網選襯壓獵鹽夢淵醖顧 ~ 糧艱廠構衊願顧醖簾鹹) 更多
NCT03887884 (Pubmed \| Clin Ther)	临床1期	帕金森病	23	CVT-301	窪蓋鹽簾構繭壓襯積構(廠夢餘顧獵簾顧蓋衊簾) = CVT-301, 7 patients [30.4%]; oral CD/LD, 1 patient [4.5%] 製鹽觸鏇顧餘製膚艱齋 (淵夢構艱鬱鏇窪願網壓 )	-	2020-06-01
				Oral Carbidopa/Levodopa